

**On-line Table 1: Demographic data and neuropsychological testing of HIV-negative CM patients and healthy controls**

	Patients (n = 15)	Controls (n = 15)	F or X value	P value
Age at follow-up (year)	54.5 ± 13.5	53.2 ± 14.0		0.792
Sex (male)	14 (93.3)	14 (93.3)		0.759
Years of education	10.9 ± 4.9	11.9 ± 4.8		0.551
WAIS-III				
General knowledge	9.7 ± 2.0	11.1 ± 3.4	0.621	0.438
Digit span	8.5 ± 3.5	11.9 ± 3.6	6.181	0.020*
Vocabulary ability	9.6 ± 3.5	11.0 ± 3.1	0.427	0.519
Arithmetic	9.7 ± 3.1	11.1 ± 2.6	2.135	0.155
Letter–number sequencing	8.1 ± 4.5	10.6 ± 4.3	1.998	0.171
Comprehension	9.7 ± 3.5	11.8 ± 3.3	1.021	0.321
Similarities	8.5 ± 4.0	10.9 ± 2.5	1.936	0.175
Picture completion	7.9 ± 3.0	10.1 ± 3.3	3.438	0.075
Matrix reasoning	9.3 ± 2.8	10.4 ± 3.2	0.778	0.386
Block design	9.1 ± 3.4	11.7 ± 2.5	5.947	0.022*
Picture arrangement	9.7 ± 2.7	10.3 ± 3.3	0.206	0.654
Digit symbol	8.9 ± 3.2	11.3 ± 3.6	3.629	0.068
Object assembly	9.3 ± 2.8	10.4 ± 3.2	0.778	0.386
Verbal Comprehension Index	96.3 ± 14.3	105.2 ± 14.7	2.707	0.112
Perceptual Reasoning Index	93.1 ± 14.9	104.5 ± 13.9	5.137	0.032*
Working Memory Index	92.3 ± 17.3	108.2 ± 17.1	6.678	0.016*
CASI				
Mental manipulation	8.7 ± 1.7	9.4 ± 1.1	2.557	0.122
Short-term memory	8.6 ± 3.5	10.4 ± 2.0	3.043	0.093
Abstract thinking	9.4 ± 2.3	10.7 ± 1.3	4.560	0.042*
Drawing	9.2 ± 1.5	9.9 ± 0.3	3.348	0.079
Semantic verbal fluencies	7.1 ± 2.7	8.7 ± 1.9	3.856	0.060
Attention	7.3 ± 1.1	7.7 ± 0.6	1.966	0.173
Language	9.8 ± 0.4	9.9 ± 0.2	1.147	0.294
Long-term memory	9.7 ± 0.7	9.7 ± 0.7	0.010	0.923
Orientation	15.8 ± 3.8	17.7 ± 1.1	3.053	0.092
CASI total score	85.6 ± 14.1	94.3 ± 5.0	5.573	0.026*
Mean cognitive scores	91.8 ± 13.7	103.0 ± 10.8	7.051	0.013*

\* indicates  $P < 0.05$ .

**On-line Table 2: Neuroimaging findings of HIV-negative CM patients following anti-fungal treatment**

Patient/Age (years)/Sex	CSF Cryptococcal-Antigen Titer	MR Imaging Finding during Acute Phase	MR Imaging Finding during Follow-Up	Intervals Between Both Discharge and Discontinue Antifungal Therapy from Hospital and Follow-Up Study (months)
1/39/M	1:8192	No active lesion	No active lesion	89
2/63/M	1:64	Meningeal/gyral enhancement (+); right basal ganglia infarction; bilateral cerebellar hyperintense; bilateral subdural effusion	Bilateral cerebellum hyperintense	43
3/65/M	1:256	Bilateral basal ganglia infarction	No active lesion	101
4/58/M	1:1024	Meningeal-gyral enhancement (+); right basal ganglia infarction; bilateral subdural effusion	Right frontal and left parietal hyperintense	72
5/72/M	1:8	Hydrocephalus (+); Meningeal-gyral enhancement (+); left temporal cerebritis	No active lesion	4
6/54/M	1:128	Meningeal-gyral enhancement (+); bilateral Vichow-Robin dilation	No active lesion	12
7/71/F	1:8	Bilateral Vichow-Robin dilation	No active lesion	96
8/56/M	1:128	Hydrocephalus (+); right subdural effusion	No active lesion	70
9/59/M	1:1024	Meningeal/gyral enhancement (+)	No active lesion	49
10/56/M	1:256	No active lesion (by CT)	No active lesion	122
11/27/M	1:1024	Hydrocephalus (+); Meningeal/gyral enhancement (+)	No active lesion	97
12/65/M	1:8	Hydrocephalus (+); meningeal/gyral enhancement (+); bilateral Vichow-Robin dilation	Meningeal/gyral enhancement (+)	60
13/57/M	1:1024	Hydrocephalus (+); Meningeal/gyral enhancement (+); cryptococcoma (+); pons, right occipital, bilateral parietal cerebritis	Meningeal/gyral enhancement (+); bilateral parietal hyperintense	3
14/45/M	1:512	Bilateral cerebellar, right parietal cerebritis	No active lesion	84
15/31/M	1:512	Meningeal/gyral enhancement (+); right Vichow-Robin dilation	Meningeal/gyral enhancement (+); right Virchow-Robin dilation	5